Therapy-activated stromal cells can dictate tumor fate

In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors, as well as invasion and metastasis.

• Publication year

  2016

• Venue

  Journal of Experimental Medicine

• Publication date

  2016-12-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20161845PMID 27881735PMCID 5154951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects

  2016cited by this paper
• Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

  2016influential reference
• Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy.

  2016cited by this paper
• Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

  2016cited by this paper
• Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials

  2015cited by this paper
• Clinical overview of metronomic chemotherapy in breast cancer

  2015cited by this paper
• Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

  2015cited by this paper
• Maintenance treatment in metastatic colorectal cancer.

  2015cited by this paper
• Metronomic chemotherapy

  2014cited by this paper
• Metronomic chemotherapy following the maximum tolerated dose is an effective anti‐tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

  2013cited by this paper
• Metronomic chemotherapy: new rationale for new directions

  2010cited by this paper
• Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.

  2009cited by this paper
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper
• Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.

  2006cited by this paper
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

  2000cited by this paper
• Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

  2000influential reference
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

  2000cited by this paper

• Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4

  2021cites this paper
• Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment

  2021cites this paper
• Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks

  2019cites this paper
• Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non‐Hodgkin lymphoma

  2019cites this paper
• Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy.

  2019cites this paper
• Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers

  2019cites this paper
• The pro-tumorigenic host response to cancer therapies

  2019cites this paper
• The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.

  2017cites this paper
• Role of vascular normalization in benefit from metronomic chemotherapy

  2017cites this paper
• The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity

  2017cites this paper